AQR Capital Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

AQR Capital Management’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,300	Closed	-$322K	–	2319
2015 Q1	$322K	Sell	3,300 -16,300	-83%	-$1.73M	﹤0.01%	1846
2014 Q4	$1.82M	Buy	19,600 +4,800	+32%	+$379K	﹤0.01%	1340
2014 Q3	$1.02M	Buy	14,800 +7,400	+100%	+$530K	﹤0.01%	1615
2014 Q2	$776K	Buy	7,400 +1,800	+32%	+$153K	﹤0.01%	1773
2014 Q1	$465K	Buy	+5,600	New	+$518K	﹤0.01%	2077
2013 Q4	–	Sell	-51,800	Closed	-$3.28M	–	2666
2013 Q3	$3.28M	Buy	51,800 +40,800	+371%	+$2.01M	0.01%	1004
2013 Q2	$462K	Buy	+11,000	New	+$501K	﹤0.01%	1930

AQR Capital Management's GEVA Position: Q2 2015 in Review

AQR Capital Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 3,300 shares — an estimated $322K sold.

AQR Capital Management first reported a position in GEVA in Q2 2013 and held it in 7 quarters. The position peaked at $3.28M in Q3 2013. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

AQR Capital Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
AQR Capital Management sold 3,300 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $322K.
AQR Capital Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 7 quarters.
AQR Capital Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $3.28M in Q3 2013.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on AQR Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.